MYH9-related disease (MYH9-RD) is a rare autosomal dominant genetic syndrome characterized by congenital thrombocytopenia associated with the risk of developing progressive nephropathy, sensorineural deafness, and presenile cataract. During the collection of a large case-series of patients with MYH9-RD we noticed several cases with unexplained elevation of liver enzymes. Our aim was to evaluate if the alteration of liver tests is a feature of the MYH9-RD and to define its clinical significance.
Methods and Findings
Data concerning liver tests, prospectively recorded in the Italian Registry for MYH9-RD, were collected and compared with those of three control populations: patients with autoimmune thrombocytopenia, patients with inherited thrombocytopenias other than MYH9-RD, and the participants to a large epidemiologic survey in an Italian geographic isolate. Thirty-eight of 75 evaluable MYH9-RD patients (50.7%) showed an elevation of ALT and/or AST, and 17 of 63 (27.0%) an increase of GGT. The increases ranged from 1.9±0.7 to 2.7±1.6 fold the upper normal limit. The prevalence of liver test alterations was significantly higher in MYH9-RD patients than in each of the control populations, with odds ratios ranging from 8.2 (95% CIs 2.2–44.8) to 24.7 (14.8–40.8). Clinical follow-up and more detailed liver studies of a subset of patients, including ultrasound liver scan, liver elastography and liver biopsy in one case, did not show any significant structural damage or evolution towards liver insufficiency.
Elevation of liver enzymes is a frequent and previously unrecognized feature of the MYH9-RD syndrome; however, this defect does not appear to have poor prognostic value.
Citation: Pecci A, Biino G, Fierro T, Bozzi V, Mezzasoma A, Noris P, et al. (2012) Alteration of Liver Enzymes Is a Feature of the Myh9-Related Disease Syndrome. PLoS ONE 7(4): e35986. doi:10.1371/journal.pone.0035986
Editor: Christian Schulz, Heart Center Munich, Germany
Received: December 12, 2011; Accepted: March 26, 2012; Published: April 25, 2012
Copyright: © 2012 Pecci et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported, in part, by grants from Fondazione Cassa di Risparmio di Perugia (Protocol nr. 2010.020.161, nr. 2009.010.0478 and nr. 2011.0137.021) to PG. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
MYH9-related disease (MYH9-RD) is an autosomal dominant disorder characterized by congenital thrombocytopenia with giant platelets associated with the risk of developing progressive nephropathy during infancy or adult life, sensorineural deafness and presenile cataract , . MYH9-RD encompasses a series of autosomal dominant macrothrombocytopenias previously considered as distinct disorders, namely May-Hegglin anomaly (MHA; MIM#155100), Sebastian Syndrome (SBS; MIM#605249), Fechtner Syndrome (FTNS; MIM#153640), and Epstein Syndrome (EPTS; MIM#135650), all deriving from mutations in the MYH9 gene encoding for the heavy chain of nonmuscle myosin-IIA (NMMHC-IIA) –. At least 44 different MYH9 mutations have been reported so far , –, which may involve either the N-terminal motor domain (MD) or the C-terminal tail domain (TD) of NMMHC-IIA. Genotype-phenotype correlation studies have shown that patients with mutations affecting the MD have more severe thrombocytopenia and higher incidence of nephropathy and deafness than those with mutations involving the TD . Myosin-IIA is a non-sarcomeric myosin expressed in most cells and tissues where it participates in functions associated with the generation of chemomechanical forces by the cytoskeleton, including cytokinesis, cell motility and maintenance of cell shape , . Studies on the murine orthologue Myh9 have shown that it is expressed in liver, kidney, lung and spleen and, at a lower level, in heart and brain, with no expression in skeletal muscle and testis . Although congenital macrothrombocytopenia, sensorineural hearing loss, nephropathy and cataract are the only recognized clinical hallmarks of the MYH9-RD syndrome, previous studies have reported altered liver function tests in single cases or small case series of patients with MYH9-RD –. During the collection of a large database of MYH9-RD patients (Italian Registry for MYH9-RD, www.registromyh9.org) we noticed several cases with unexplained elevated liver enzymes. Aims of the present study were to carry out a systematic evaluation of the prevalence of alterations of liver enzymes in a large, well-characterized MYH9-RD population, to compare it with the prevalence observed in a large population survey performed in central eastern Sardinia  and in two populations of patients with thrombocytopenias not related to MYH9 mutations studied during the same period at the authors' Centers, and to assess the evolution of the liver test alterations in terms of potential organ damage.
The study included all the consecutive patients enrolled in the Italian Registry for MYH9-RD for which data concerning liver function were available. Diagnosis of MYH9-RD was confirmed in all patients by both immunofluorescence screening test and molecular analysis , , . Most patients have been already reported (Table 1). The study was approved by the Ethic Committee of the IRCCS Policlinico San Matteo Foundation, Pavia; written informed consent was obtained from all the patients or their legal guardians. As a control, data from the participants to the Ogliastra cross-sectional epidemiologic survey, carried out in central eastern Sardinia between with 2002 and 2008, were used , . In addition, data of liver enzymes of MYH9-RD patients were compared with those of two populations of consecutive patients with MYH9-RD-unrelated thrombocytopenias studied during the same period at the authors' institutions, for which we had single or repeated liver enzyme determinations: one with acquired immune thrombocytopenia (ITP), the other with different forms of inherited thrombocytopenia .
Liver studies in MYH9-RD patients
At the moment of the collection of data, the Italian Registry for MYH9-RD included 184 patients. The following data were extracted from the database: alanine aminotrasferase (ALT), aspartate aminotrasferase (AST) and gamma-glutamyltransferase (GGT). Elevation of liver enzymes was defined as a value above the upper normal limit (UNL) of the reference laboratories where the tests were carried out. The UNLs were established by the participant laboratories based on the 95th percentile distribution of the serum concentrations of these enzymes in healthy blood donors in their respective geographic areas. In all patients medical history was recorded and physical examination was performed. Moreover, whenever available the results of liver ultrasound assessment and of additional biochemical tests were collected. These latter included: viral hepatitis markers (antibodies to HCV, HBV surface antigen, antibodies to HBV core antigen), antinuclear antibodies, anti-smooth muscle cell antibodies, anti-mitochondrial antibodies, anti-LKM and anti-microsomal antibodies, cupremia and plasma ceruloplasmin, serum α1-antitrypsin levels, serum ferritin and saturated ferritin, thyroid hormones, and anti-endomisium and anti-transglutaminase antibodies. All patients for which a known cause of elevation of liver enzymes was identified (e.g. infectious hepatitis, excessive alcohol intake, drug addiction, gallstone disease, metabolic syndrome, celiac disease, congestive heart failure, exposure to liver toxic agents) were excluded from the analysis.
Liver transient elastography (Fibroscan) was carried out in two patients and liver biopsy in one single case. Immunostaining for NMMHC-IIA was performed on paraffin-embedded liver sections by the PRB440P rabbit polyclonal antibody (Covance Research Products, Berkeley, CA, USA) diluted 1:200 in PBS. The horseradish peroxidase LSAB 2 kit (Dako, Glostrup, Denmark) was used for secondary detection. The biopsy used as a control was an unaffected liver sample collected as part of the diagnostic procedures for clinical reasons unrelated to the present study and processed for staining after patient's informed consent.
Liver studies in the control populations
The criteria for defining liver enzymes elevation in the three control populations were the same as for MYH9-RD patients. For the Ogliastra inhabitants, data of serum GGT were not available. For the participants to the Ogliastra survey, medical history was collected by a physician at the time of measurement of liver enzymes: subjects who referred a history of one of the known causes of liver damage listed above were excluded from the study.
Continuous variables are reported as means ± standard deviation; categorical variables as total numbers and percentages. We explored the distribution of liver enzymes levels in the different patient populations examined. Possible associations between alterations of liver enzymes and the specific MYH9 mutation, the residue of the NMMHC-IIA protein affected by mutation, the exon of MYH9 involved by mutation, or the involved domain were investigated by Chi square test, after proper grouping of the MYH9 mutations. Odds ratios (ORs) along with Chi square tests were used to assess differences in liver enzyme alterations between MYH9-RD patients and control populations, even excluding patients who underwent transfusion or receiving specific drugs to treat the clinical consequences of MYH9 mutations. In addition, logistic regression was performed to take into account the potential confounding effect of age and sex.
Eighty-nine out of the 184 patients of the MYH9-RD registry had liver function tests recorded. Fourteen of them were excluded from the analysis because of the presence of an identifiable cause of liver damage (positive serology for HBV or HCV, alcohol or drug addiction, congestive heart failure).
Therefore, a total of 75 MYH9-RD patients belonging to 52 unrelated families were studied. Table 1 and 2 summarize their basic genotypic and clinical features. Liver enzymes data were compared with those of 7257 subjects from the Ogliastra population, 77 patients with ITP, and 32 patients with different forms of inherited thrombocytopenia not related to MYH9 mutations. These included monoallelic Bernard-Soulier syndrome  (12 patients), autosomal-dominant thrombocytopenia deriving from ANKRD26 mutations (11 patients), autosomal-dominant macrothrombocytopenia due to ITGB3 mutation  (3 patients), and autosomal-dominant macrothrombocytopenia of undefined origin (6 patients) , . Basic demographic features of the study populations are summarized in Table 3.
Liver test alterations in the MYH9-RD population
Thirty-eight out of 75 MYH9-RD patients (50.7%) presented an increase of AST or ALT in at least one determination (Table 4). ALT was the most frequently altered aminotransferase, since it was increased in 35 subjects (46.7%); twenty-nine of them (38.7% of total) had also a simultaneous increase of AST. Three patients (4%) showed an increase of only AST.
Serum GGT was measured in 63 cases and found to be increased in 17 of them (27%). In particular, GGT was altered in 16 of the 32 evaluable subjects with an increase of aminotransferases (50%), while only one patient had isolated increase of GGT. The mean increase of aminotransferases was 1.9 (SD 0.7) fold the UNL for ALT and 1.4 (SD 0.4) for AST, while GGT were increased 2.7 fold (SD 1.6).
Among patients with alteration of liver enzymes, a total of 29 subjects had liver enzymes measured repeatedly (from 1 to 9 times, average 3.1, with intervals from 2 to 150 months, average 43.6 months) (Table 5). Out of these, 20 patients (69%) presented a stable picture of enzymatic alteration, with increased liver enzymes in all the measurements (mean number of repeated measurements, 2.9; mean interval, 34 months after the first measurement); four patients (17%) had a fluctuating enzymatic pattern, with normal findings at some of the intermediate measurements, while 5 patients (17%) experienced a normalization of the liver enzyme alterations after a mean observation time of 19.2 months. In none of the patients a clear worsening trend or a clinically relevant alteration of liver function was observed.
Out of the 39 patients (belonging to 31 families) with alteration of liver enzymes, 56% were males and had a mean age of 30.5 years; 9 patients were 16 years-old or less. MYH9-RD patients with and without liver alterations did not differ significantly for gender, platelet count, and presence of other extra-hematological manifestations of MYH9-RD; moreover, no association was found between alterations of liver enzymes and patients' age (data not shown). There was no evident association between the elevation of liver enzymes (prevalence or degree of elevation) and the specific MYH9 mutation, the residue of the NMMHC-IIA protein affected by mutation, or the involved domain (MD or TD, Figure 1). However, when causative mutations were grouped by the involved exon of MYH9, mutations of exon 25 (T1155I, T1155A, and R1162T) were associated with a higher prevalence of elevation of both aminotrasferases (p = 0.04) and with a higher level of increase of ALT (p = 0.02); a nearly significant association was observed also for a higher elevation of AST (p = 0.07). A possible cosegregation of mutations of exon 25 with altered liver enzymes, however, needs confirmation since only 4 patients with mutations involving this exon were analyzed.
Mutations involving the motor domain and tale domain regions of the gene are indicated. No significant differences in the distribution of liver test alteration between the two locations of the gene defect were evident.
Prevalence of liver test alterations in the control populations
The prevalence of liver enzyme elevations in the Ogliastra population is reported in Table 4. A total of 393 out of 7257 subjects presented an alteration of ALT or AST in at least one determination (5.4%). The most frequent alteration was an increase of ALT (320 subjects, 4.4%), and 139 cases (1.9%) had a simultaneous increase of both aminotransferases. The remaining 73 subject (1.0%) showed an isolated elevation of AST. For subjects with liver enzymes above normal, the mean value was 1.7±0.7 fold the UNL for ALT and 1.5±0.7 for AST.
In the control group of patients with ITP, 5 out of 77 patients (6.5%) presented an alteration of ALT, while none of them had increased AST (Table 4). An isolated elevation of GGT was present in 4 of the 71 patients (5.6%) in which liver test was performed. For subjects with liver enzymes above normal, the average value was 1.34±0.1 fold the UNL for ALT, and 1.49±0.2 for GGT. When repeated enzyme measurements were carried out, only 1/20 patients (5%) presented an alteration in at least two determinations and none had a persistent alteration in all the determinations carried out.
In the control group of patients with MYH9-unrelated inherited thrombocytopenias, 3 out of 32 evaluable patients (9.4%) had an increase of at least one aminotransferase (Table 4). The most frequent alteration was an increase of ALT, which was present in three subjects (9.4%), one of which had also elevated AST, while none of the 26 evaluable patients had increased GGT. The mean increase was 1.48±0.12 fold the UNL for ALT and 2.18 for AST.
The OR to have an ALT elevation for MYH9-RD patients as compared to each of the three different control populations ranged from 8.2 to 18.9, to have an AST elevation from 21.6 to 24.7 and to have an elevation of at least one of ALT or AST from 8.0 to 14.8 (p<0.0003, at least) (Table 6). The OR to have an elevation of both aminotransferases ranged from 17.7 to 32.3 (p<0.0004, at least). When adjusted for age and sex the ORs to have a liver test alteration for MYH9-RD patients was even higher, ranging from 8.5 to 41.6 (not shown).
The analysis of the distribution curve of liver enzyme levels in the different populations showed a markedly altered distribution in MYH9-RD patients, with a flat, tendentially bimodal distribution as compared with a rather typical Gaussian distribution in the ITP, inherited thrombocytopenias and Ogliastra populations (Fig. 2).
Data for ALT, AST and GGT distributions are shown.
We also evaluated whether the increased prevalence of altered liver enzymes in MYH9-RD patients could be due to a higher prevalence of patients who underwent transfusion of blood products and therefore exposed to transfusion-related liver damage. In fact, 17 of the 75 investigated MYH9-RD patients (22.6%), 26 of 77 ITP patients (33.8%) and 4 of 32 subjects with other inherited thrombocytopenias (12.5%) had undergone platelet or red blood cell transfusions (a prevalence of transfused patients not significantly different between the three groups). Medical history about transfusions was not available for the Ogliastra population. The strongly increased prevalence and degree of elevation of liver enzymes in MYH9-RD patients with respect to each of the control populations was confirmed also when the analysis was restricted to the patients who had never undergone transfusions, even assuming that none of the subjects of the Ogliastra population received transfusions. Limiting the analysis to not transfused patients, the ORs to have a liver test alteration for MYH9-RD patients as compared with the control population ranged from 8.2 to 27.7 (p<0.001). Moreover, within the MYH9-RD population, no significant difference in the elevation of liver enzymes was observed between transfused and non-transfused patients (data not shown), demonstrating that previous transfusion did not exert a significant role in liver test alterations in our case series.
Finally, we considered the hypothesis that the increased frequency of markers of liver damage in MYH9-RD subjects could be secondary to the confounding effect of potentially hepatotoxic drugs administered to treat the clinical consequences of the MYH9 mutations. In fact, 3 out of 75 MYH9-RD patients were under immunosuppressive treatment for a previous kidney transplantation and 8 were treated with ACE-inhibitors and/or angiotensin receptor blockers for proteinuria . However, the strong association between MYH9 mutations and alterations of liver enzymes was confirmed even when the analysis was restricted to patients not receiving any permanent drug treatment (data not shown).
Additional liver studies in patients with MYH9-RD
Twenty-one out of 39 (53.8%) MYH9-RD patients with liver test abnormalities had a liver ultrasound examination carried out at least once. Of these 18 had normal findings and 3 presented a mild liver steatosis, defined as a “bright liver". Sometimes mildly enlarged liver, with fine tightly packed echoes that made the liver more echoic than the right kidney, was reported. Two patients had liver transient elastography (Fibroscan) carried out on one occasion: the median stiffness was within the normal range (F0).
Thirty-six of the 39 (92.3%) patients with altered liver tests had serum tests for B and C hepatitis: all of them were negative.
A total of 21 patients underwent the more detailed biochemical studies listed under methods: in all of them all these examinations resulted normal.
In one patient, because of persistently elevated liver enzymes, a laparoscopic liver biopsy was performed after prophylactic transfusion of platelet concentrates. The patient was a 10-years-old boy with the p.T1155A MYH9 substitution and a 6-years history of persistently elevated ALT (59–303 U/L, UNL 38), AST (54–141 U/L, UNL 38), and GGT (136–151 U/L, UNL 50). Serum alkaline phosphatase was also slightly elevated, while bilirubin and cholinesterase were always within the normal range. He underwent all the examinations listed above, plus viral serology for HAV, CMV, EBV, cupruria, blood and urine aminoacid, all of which resulted normal. Histopathology revealed a preservation of hepatic architecture with scattered hepatocytes showing micro-macrovacuolar steatosis. Mild fibrosis was evident in the portal spaces and around the terminal veins. No inflammation, necrosis, apoptosis, regeneration or cholestasis were detectable, and the copper content was normal. Immunochemistry for NMMHC-IIA showed a positive reaction concentrated close to the hepatocytes' plasma membrane, particularly in the region of bile canaliculi. Cholangiocytes showed positivity mainly on the luminal side of plasma membrane. No significant differences in NMMHC-IIA distribution were detectable with respect to the liver biopsy used as a control (Fig. 3).
Liver biopsy from a 10-years-old patient with MYH9-RD caused by the p.T1155A mutation of MYH9 with persistently elevated AST, ALT and GGT. (A, B): Immunohistochemistry for NMMHC-IIA showed a signal (brown, horseradish peroxidase staining) concentrated close to the hepatocytes' plasma membrane. The distribution of NMMHC-IIA was not significantly different from that from a healthy control (C, D). Specimens were counterstained with Meyer's haematoxylin. Scale bars correspond to 10 µm.
Our study in a large, well-characterized population of patients with MYH9-RD, highlighted a high prevalence of unexplained liver enzyme alterations, with over one half of patients showing abnormal serum enzyme levels suggestive of possible liver damage.
The prevalence of liver enzyme alterations in this population compares well or is even higher than that of the recognized non-congenital manifestations of the MYH9-RD syndrome, namely renal, hearing, and ocular defects, which are present in 16 to 60% of MYH9-RD patients , .
When compared with two different control populations of patients with thrombocytopenias from different causes, one with inherited thrombocytopenias other than MYH9-RD and the other with immune thrombocytopenia, or with a large population of people from a Sardinian geographic isolate, the ORs to have an elevation of liver enzymes for MYH9-RD patients ranged from 8.2 to 24.7, a highly significant increased risk. When adjusted for age and sex, the ORs were even higher, ranging from 8.5 to 41.6. No associated causes of liver enzyme alterations were detected, even upon more detailed liver studies, including repeated liver ultrasound or in two cases liver elastography and in one liver biopsy. Finally, a follow-up ranging from 2 to 150 months (mean 44) showed no trend towards a worsening of the observed liver test alterations.
These data indicate that an elevation of liver enzymes is a feature of the clinical spectrum of MYH9-RD, but that this alterations seem benign, with no significant evolution towards clinically relevant liver damage or dysfunction. Indeed, even in MYH9-RD patients of an advanced age, in which an elevation of liver enzymes was detected since the first diagnosis of their disease, there was not one single case developing liver failure. Differently from what happens with the other clinical features of the disease which are more severe in patients carrying MYH9 mutations affecting the MD of the protein, no clear genotype/phenotype correlations were evident for the elevation of liver enzymes; however, a possible cosegregation of the mutations involving exon 25 with altered liver enzymes seems to emerge but this needs confirmation since only 4 patients with mutations involving this exon were analyzed.
Our study has some potential limitations: MYH9-RD patients may undergo platelet or blood transfusions more frequently than healthy controls during their lifetime, and therefore they may more prone to transfusion-related infectious liver injury. However, the strongly increased prevalence of altered liver enzymes in MYH9-RD patients was confirmed even when the analysis was restricted to patients that had never received platelet or blood transfusions. Moreover, the vast majority of our MYH9-RD patients (92.3%) had been tested for B and C viral hepatitis, and all those found positive were excluded from the analysis. In addition, even assuming that the three subjects that had not been tested were all HBV or HCV positive, the proportion of MYH9-RD patients with unexplained liver enzyme elevation remains significantly higher than that of controls (data not shown). Finally, the possible confounding effect of potentially hepatotoxic drugs administered to treat the clinical consequences of MYH9 mutations could reasonably be ruled out. Another limitation is that a laboratory follow-up was available for only a fraction of the MYH9-RD population and that follow-up was not of a sufficient duration (maximum 150 months) to exclude a possible late worsening of liver function. However, the observations that in a large case-series of MYH9-RD patients, including cases aged 80 or more, not one single case evolved into liver failure/cirrhosis and that imaging studies never showed significant liver structural alterations suggest that liver test alterations in this genetic syndrome do not lead to liver function impairment. This differs from kidney involvement in MYH9-RD, which, when occurs, tends to evolve progressively into end-stage renal failure , . Of course a definitive conclusion on the benign course of liver involvement in MYH9-RD requires confirmatory studies in large case series with longer follow-up.
In the hepatocytes non-muscle myosin of class II has well-recognized functions correlated with bile secretion. Myosin II was found to be enriched in the actin microfilament network around the bile canaliculus and was identified as the essential motor for the bile canalicular contraction –. Moreover, myosin II is involved in vesicle trafficking between the cytoplasmic compartment and plasma membrane and regulates the apical membrane expression of several transporters associated with bile secretion, such as the bile salt export pump, whose genetic defects are associated with some forms of familiar intrahepatic cholestasis , . Recent studies identified additional key roles for myosin II in hepatocytes, since it was implicated in postnatal hepatocytes polyploidization  spatial reorganization of hepatocytes during development and liver regeneration , and cell cycle progression and motility , . Although we have no data to provide a mechanistic explanation of liver enzyme alterations in MYH9-RD, the observation that the myosin IIA loss-of-function of MYH9-RD patients primarily results in a phenotype consistent with hepatocellular damage rather than a cholestatic disease seems more consistent with the functions of myosin in hepatocyte polyploidization, regeneration, cell cycle and motility –.
In conclusion, our study shows that an alteration of liver enzymes is a feature of the MYH9-RD syndrome, a defect however that does not appear to have a poor prognostic value.
Conceived and designed the experiments: AP CB PG GB. Performed the experiments: TF VB PN UR GL FF MP AS UM SM AM AP. Analyzed the data: AP CB PG GB. Contributed reagents/materials/analysis tools: SM AP. Wrote the paper: PG AP CB.
- 1. Seri M, Pecci A, Di Bari F, Cusano R, Savino M, et al. (2003) MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) 82: 203–15.
- 2. Pecci A, Panza E, Pujol-Moix N, Klersy C, Di Bari F, et al. (2008) Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 29: 409–17.
- 3. Kelley MJ, Jawien W, Ortel TL, Korczak JF (2000) Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet 26: 106–8.
- 4. Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, et al. (2000) Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Hegglin/Fechtner Syndrome Consortium. Nat Genet 26: 103–5.
- 5. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, et al. (2001) Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin Anomaly and Fechtner, Sebastian, Epstein and Alport-like syndromes. Am J Hum Genet 69: 1033–45.
- 6. Balduini CL, Pecci A, Savoia A (2011) Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 154: 161–174.
- 7. Kunishima S, Matsushita T, Kojima T, Sako M, Kimura F, et al. (2003) Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations. Lab Invest 83: 115–22.
- 8. Burt RA, Joseph JE, Milliken S, Collinge JE, Kile BT (2008) Description of a novel mutation leading to MYH9-related disease. Thromb Res 122: 861–3.
- 9. Savoia A, De Rocco D, Panza E, Bozzi V, Scandellari R, et al. (2010) Heavy chain myosin 9-related disease (MYH9-RD): neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder. Thromb Haemost 103: 826–32.
- 10. Sellers JR (2000) Myosins: a diverse superfamily. Biochim Biophys Acta 1496: 3–22.
- 11. Jacobelli J, Chmura SA, Buxton DB, Davis MM, Krummel MF (2004) A single class II myosin modulates T cell motility and stopping, but not synapse formation. Nat Immunol 5: 531–8.
- 12. D'Apolito M, Guarnieri V, Boncristiano M, Zelante L, Savoia A (2002) Cloning of the murine non-muscle myosin heavy chain IIA gene ortholog of human MYH9 responsible for May-Hegglin, Sebastian, Fechtner, and Epstein syndromes. Gene 286: 215–22.
- 13. Gershoni-Baruch R, Baruch Y, Viener A, Lichtig C (1988) Fechtner syndrome: clinical and genetic aspects. Am J Med Genet 31: 357–67.
- 14. Rocca B, Laghi F, Zini G, Maggiano N, Landolfi R (1993) Fechtner syndrome: report of a third family and literature review. Br J Haematol 85: 423–6.
- 15. Toren A, Amariglio N, Rozenfeld-Granot G, Simon AJ, Brok-Simoni F, et al. (1999) Genetic linkage of autosomal-dominant Alport syndrome with leukocyte inclusions and macrothrombocytopenia (Fechtner syndrome) to chromosome 22q11–13. Am J Hum Genet 65: 1711–7.
- 16. Biino G, Balduini C, Casula L, Cavallo P, Vaccargiu S, Parracciani D, et al. (2011) Analysis of 12517 inhabitants of a Sardinian geographic isolate reveals that propensity to develop mild thrombocytopenia during ageing and to present mild, transient thrombocytosis in youth are new genetic traits. Haematologica 96: 96–101.
- 17. Pecci A, Noris P, Invernizzi R, Savoia A, Seri M, et al. (2002) Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool for MYH9-related disorders. Br J Haematol 17: 164–7.
- 18. Angius A, Melis PM, Morelli L, Petretto E, Casu G, et al. (2001) Archival, demographic and genetic studies define a Sardinian sub-isolate as a suitable model for mapping complex traits. Hum Genet 109: 198–209.
- 19. Savoia A, Balduini CL, Savino M, Noris P, Del Vecchio M, et al. (2001) Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 97: 1330–5.
- 20. Noris P, Perrotta S, Seri M, Pecci A, Gnan C, et al. (2011) Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood 117: 6673–6680.
- 21. Gresele P, Falcinelli E, Giannini S, D'Adamo P, D'Eustacchio A, et al. (2009) Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica 94: 663–9.
- 22. Balduini CL, Cattaneo M, Fabris F, Gresele P, Iolascon A, Pulcinelli FM, et al. (2003) Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 88: 582–92.
- 23. Noris P, Pecci A, Di Bari F, Di Stazio MT, Di Pumpo M, et al. (2004) Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica 89: 1219–25.
- 24. Pecci A, Granata A, Fiore CE, Balduini CLRenin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrol Dial Transplant 2008;23: 2690–2.
- 25. Tsukada N, Ackerley CA, Phillips MJ (1995) The structure and organization of the bile canalicular cytoskeleton with special reference to actin and actin-binding proteins. Hepatology 21: 1106–13.
- 26. Tsukada N, Azuma T, Phillips MJ (1994) Isolation of the bile canalicular actin-myosin II motor. Proc Natl Acad Sci U S A 91: 6919–23.
- 27. Watanabe S, Miyazaki A, Hirose M, Takeuchi M, Ohide H, et al. (1991) Myosin in hepatocytes is essential for bile canalicular contraction. Liver 11: 185–9.
- 28. Subramanian VS, Marchant JS, Said HM (2010) Molecular determinants dictating cell surface expression of the human sodium-dependent vitamin C transporter-2 in human liver cells. Am J Physiol Gastrointest Liver Physiol 298: G267–74.
- 29. Chan W, Calderon G, Swift AL, Moseley J, Li S, et al. (2005) Myosin II regulatory light chain is required for trafficking of bile salt export protein to the apical membrane in Madin-Darby canine kidney cells. J Biol Chem 280: 23741–7.
- 30. Margall-Ducos G, Celton-Morizur S, Couton D, Brégerie O, Desdouets C (2007) Liver tetraploidization is controlled by a new process of incomplete cytokinesis. J Cell Sci 120: 3633–9.
- 31. Herrema H, Czajkowska D, Théard D, van der Wouden JM, Kalicharan D, et al. (2006) Rho kinase, myosin-II, and p42/44 MAPK control extracellular matrix-mediated apical bile canalicular lumen morphogenesis in HepG2 cells. Mol Biol Cell 17: 3291–303.
- 32. Bhadriraju K, Hansen LK (2004) Extracellular matrix-dependent myosin dynamics during G1-S phase cell cycle progression in hepatocytes. Exp Cell Res 300: 259–71.
- 33. Török N, Urrutia R, Nakamura T, McNiven MA (1996) Upregulation of molecular motor-encoding genes during hepatocyte growth factor- and epidermal growth factor-induced cell motility. J Cell Physiol 167: 422–33.